Dilan A. Patel
YOU?
Author Swipe
View article: Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma
Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma Open
Introduction The LEO Comorbidity Index (LCI), comprising ten equally weighted comorbidity categories (respiratory, cardiovascular, digestive, hepatic, renal, autoimmune, diabetes, cancer history, HIV, and stroke), has demonstrated prognost…
View article: Enhancing CI/CD security with provenance metadata and supply chain best practices
Enhancing CI/CD security with provenance metadata and supply chain best practices Open
Continuous Integration and Continuous Delivery (CI/CD) pipelines have transformed modern software development by enabling faster release cycles, increased collaboration, and improved automation. However, these benefits also introduce compl…
View article: AI-driven incident response in cloud security
AI-driven incident response in cloud security Open
The proliferation of cloud computing has revolutionized the way businesses manage and deliver IT services, enabling dynamic scalability, ubiquitous access, and cost-effective infrastructure. However, the same attributes that make cloud com…
View article: Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma Open
Background: Mosunetuzumab (Mosun) is an anti-CD3xCD20 bispecific antibody with FDA accelerated approval as intravenous (IV) treatment for patients with relapsed/refractory (r/r) follicular lymphoma (FL) after 2+ lines of therapy. Recent st…
View article: Severe acute cutaneous only graft-<i>versus</i>-host disease after late relapse of chronic myeloid leukemia and ultraviolet B phototherapy
Severe acute cutaneous only graft-<i>versus</i>-host disease after late relapse of chronic myeloid leukemia and ultraviolet B phototherapy Open
Not available.
View article: Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager
Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager Open
Off-the-shelf immunotherapeutics that suppress tumor growth and provide durable protection against relapse could enhance cancer treatment. We report preclinical studies on a CD33 x CD3 bivalent bispecific diabody, AMV564, that not only sup…
View article: Immune Adjuvant Therapy With Interleukin-7 in a Lymphopenic Patient With Aplastic Anemia and Mucormycosis
Immune Adjuvant Therapy With Interleukin-7 in a Lymphopenic Patient With Aplastic Anemia and Mucormycosis Open
BACKGROUND: We report the case of a patient with aplastic anemia and pancytopenia on immune-suppressive therapy who developed invasive pulmonary infection with mucormycosis and was treated with immune adjuvant therapy. CASE SUMMARY: Given …
View article: Peer Review #3 of "Myofascial release versus Mulligan sustained natural apophyseal glides’ immediate and short-term effects on pain, function, and mobility in non-specific low back pain (v0.1)"
Peer Review #3 of "Myofascial release versus Mulligan sustained natural apophyseal glides’ immediate and short-term effects on pain, function, and mobility in non-specific low back pain (v0.1)" Open
Background: Myofascial release (MFR) and Mulligan Sustained Natural Apophyseal Glides (SNAGs) are manual therapy techniques routinely practiced in the management of non-specific low back pain (NSLBP).,As a solo intervention or along with o…
View article: New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide Open
Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new‐onset posttransplant diabet…
View article: Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease
Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease Open
Hematopoietic cell transplant (HCT) can cure both children and adults with sickle cell disease. Outcomes have historically been poor for the vast majority of patients who lack a matched sibling donor. However, the development of haploident…
View article: Non-Myeloablative Bone Marrow Transplant with Post-Transplant Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Transfusion Dependent Thalassemia: Results of an International Consortium (VGC2)
Non-Myeloablative Bone Marrow Transplant with Post-Transplant Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Transfusion Dependent Thalassemia: Results of an International Consortium (VGC2) Open
BackgroundPost-transplant cyclophosphamide (PTCy) enables allogeneic hematopoietic cell transplant (Allo-HCT) across the human leukocyte antigen barrier. Allo-HCT for severe transfusion dependent thalassemia is restricted in its applicatio…
View article: Inferior Outcomes for Patients Developing New-Onset Post-Transplant Diabetes Mellitus after Haploidentical Hematopoietic Cell Transplant
Inferior Outcomes for Patients Developing New-Onset Post-Transplant Diabetes Mellitus after Haploidentical Hematopoietic Cell Transplant Open
The mortality rate triples for the 50% of patients diagnosed with new-onset post-transplant diabetes mellitus (PTDM) after HLA-identical allogeneic hematopoietic cell transplant (HCT) (Griffith, BBMT 2011). Haploidentical HCT (haplo-HCT) w…
View article: Dural Marginal Zone Lymphoma in a Patient With a Hepatitis C Virus Infection
Dural Marginal Zone Lymphoma in a Patient With a Hepatitis C Virus Infection Open
Primary dural marginal zone lymphomas (MZLs) are exceptionally rare, with fewer than 100 cases reported to date. While the association between hepatitis C virus (HCV) infection and lymphoma is well established, it is unclear if this associ…
View article: Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone Open
Multiple myeloma is a common plasma cell malignancy with a median overall survival of fewer than 10 years. Proteasome inhibitors comprise an important part of the treatment regimen for this disease. The present study reports the case of a …
View article: Early viral reactivation despite excellent immune reconstitution following haploidentical Bone marrow transplant with post‐transplant cytoxan for sickle cell disease
Early viral reactivation despite excellent immune reconstitution following haploidentical Bone marrow transplant with post‐transplant cytoxan for sickle cell disease Open
Background Haploidentical bone marrow transplant (haplo‐BMT) offers near universal donor availability as a curative modality for individuals with severe sickle cell disease (SCD). However, the required intense immunodepletion is associated…
View article: Improvement in processing speed following haploidentical bone marrow transplant with posttransplant cytoxan in children and adolescents with sickle cell disease
Improvement in processing speed following haploidentical bone marrow transplant with posttransplant cytoxan in children and adolescents with sickle cell disease Open
The authors declare that there is no conflict of interest.
View article: T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?
T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we? Open
Introduction: Severe sickle cell disease is associated with progressive end-organ damage and early mortality in adults. While allogeneic hematopoietic cell transplant from a matched related donor is curative, the vast majority of patients …
View article: Augmenting Non-Myeloablative BMT with Ptcy Using Thiotepa or 400 Cgy TBI Improves Engraftment in Patients with Transfusion Dependent Thalassemia: Results of a Haploidentical Transplant Consortium for Hemoglobinopathies (ICHH)
Augmenting Non-Myeloablative BMT with Ptcy Using Thiotepa or 400 Cgy TBI Improves Engraftment in Patients with Transfusion Dependent Thalassemia: Results of a Haploidentical Transplant Consortium for Hemoglobinopathies (ICHH) Open
IntroductionPost-transplant cyclophosphamide (PTCy) enables blood and marrow transplantation (BMT) across the HLA barrier. BMT for transfusion dependent thalassemia (TDT) is restricted due to limited donor availability, graft rejection, an…
View article: Delayed Immune Reconstitution and Increased Viral Infections Following Haploidentical BMT with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Results of a Haploidentical Transplant Consortium for Hemoglobinopathies (ICHH)
Delayed Immune Reconstitution and Increased Viral Infections Following Haploidentical BMT with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Results of a Haploidentical Transplant Consortium for Hemoglobinopathies (ICHH) Open
IntroductionHaploidentical bone marrow transplant (haplo-BMT) with post-transplant cyclophosphamide (PTCy) has increased curative options for patients with sickle cell disease (SCD), with near universal donor availability. However, this ap…
View article: Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?
Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going? Open
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) offers universal donor availability and can potentially cure relapsed or primary refractory Hodgkin lymphoma (HL) and non-Hodg…